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Abstract
Background: The Philadelphia chromosome−negative myeloproliferative neoplasms (MPN) myelofibrosis (MF),
polycythemia vera (PV), and essential thrombocythemia (ET) negatively affect patient quality of life (QoL) and are
associated with increased risk of mortality.
Methods: The MPN Landmark survey was conducted from May to July 2014 in patients with MF, PV, or ET under
active management in the United States. The survey assessed respondent perceptions of disease burden and
treatment management and included questions on overall disease burden, QoL, activities of daily living, and work
productivity. Outcomes were further analyzed by calculated (ie, not respondent-reported) prognostic risk score and
symptom severity quartile.
Results: The survey was completed by 813 respondents (MF, n = 207; PV, n = 380; ET, n = 226). The median
respondent age in each of the 3 MPN subtypes ranged from 62 to 66 years; median disease duration was 4 to
7 years. Many respondents reported that they had experienced MPN-related symptoms ≥1 year before diagnosis
(MF, 49 %; PV, 61 %; ET, 58 %). Respondents also reported that MPN-related symptoms reduced their QoL, including
respondents with low prognostic risk scores (MF, 67 %; PV, 62 %; ET, 57 %) and low symptom severity (MF, 51 %; PV,
33 %; ET, 15 %). Many respondents, including those with a low prognostic risk score, reported that their MPN had
caused them to cancel planned activities or call in sick to work at least once in the preceding 30 days (cancel
planned activities: MF, 56 %; PV, 35 %; ET, 35 %; call in sick: MF, 40 %; PV, 21 %; ET, 23 %).
Conclusions: These findings of the MPN Landmark survey support previous research about the symptom burden
experienced by patients with MPNs and are the first to detail the challenges that patients with MPNs experience
related to reductions in activities of daily living and work productivity.
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Background
Myelofibrosis (MF), polycythemia vera (PV), and essen-
tial thrombocythemia (ET) are Philadelphia chromo-
some−negative myeloproliferative neoplasms (MPNs)
that are frequently associated with the JAK2V617F muta-
tion [1]. Presentations and symptom profiles of these
MPNs vary with subtype but often include erythrocyto-
sis, thrombocytosis, leukocytosis, and/or splenomegaly
[1, 2]. Prevalence of PV and ET is approximately 10
times higher than MF; prevalence per 100,000 residents
in the United States (2008–2010) was 4 to 6 people for
MF, 45 to 57 for PV, and 39 to 57 for ET [3].
Patients with MPNs experience a broad array of symp-
toms that negatively affect their quality of life (QoL) [2].
Symptoms often include fatigue, concentration prob-
lems, night sweats, pruritus, and splenomegaly-related
symptoms (eg, early satiety and abdominal discomfort
and/or pain) [4, 5]. In addition, patients with MF, PV, or
ET have increased risk of mortality compared with the
general population [6]. Cardiovascular events and fi-
brotic and/or leukemic transformation are important
causes of morbidity and mortality in patients with MPNs
[7–9]. One study reported that median survival is ap-
proximately 6 years for patients with MF (median age at
diagnosis, 63 years; median follow-up, 8 years); 14 years
for patients with PV (median age at diagnosis, 64 years;
median follow-up, 12 years); and 20 years for patients
with ET (median age at diagnosis, 55 years; median
follow-up, 17 years) [10].
Numerous questions remain regarding myeloprolifera-
tive disease burden and management. A limited amount
of data about the extent to which MPNs affect activities of
daily living are available in the published literature [11],
and we are unaware of any published reports about the
productivity of patients with MPNs who are employed.
Methods for identifying high-risk patients have been de-
veloped based on known risk factors [12–14] and symp-
tom severity [15]. Prognostic risk score models have been
proposed for MF [12], PV [13], and ET [14]; however, the
predictive value of these systems for identifying compre-
hensive patient burden that includes QoL and productivity
impairments has not been evaluated.
The MPN Landmark survey evaluated the patient dis-
ease burden in the Philadelphia chromosome–negative
MPN disease setting. This first analysis of the MPN
Landmark survey includes data concerning the impact
of MPNs on health and productivity as reported by a




Patients in the United States with a previous diagnosis
of MF, PV, or ET were eligible to take the survey.
Respondents were recruited through physician offices,
advocacy groups, and the media. Invitations to complete
a web-based survey were delivered by direct mail to pa-
tients nationwide. Digital recruiting was conducted on-
line at 50 websites and a print ad campaign was
conducted across 13 newspapers in 5 major metropol-
itan regions (Chicago, IL; Dallas, TX; Houston, TX;
Philadelphia, PA; and New York, NY). To supplement
the multichannel recruitment effort, 1500 additional in-
vitations were distributed through specialists who were
treating patients with MPNs. Surveys were administered
online and completed between May and July 2014; re-
spondents did not receive remuneration for participat-
ing. Investigators were blinded to the method by which
individual respondents were recruited, and the survey
did not ask respondents to report their recruitment
method.
Survey instrument
A web-based survey that included 65 multiple-choice
questions with an estimated completion time of 20 to
25 minutes was presented to each respondent. A sum-
mary of the patient respondent portion of the MPN
Landmark survey is included in the Additional file 1: Re-
spondents answered questions tailored to their diagno-
sis—MF, PV, or ET. The current report includes
observational findings from respondents based on ques-
tions related to (1) respondent demographics; (2) disease
features; (3) symptom burden; (4) disease burdens re-
lated to QoL, activities of daily living, and work product-
ivity; and (5) treatment management and therapies.
Individual MPN-related symptoms were evaluated using
an adapted version of the MPN Symptom Assessment
Form (MPN-SAF) [5] and were rated on a scale that
ranged from 0 (absent) to 10 (worst imaginable); based
on the structure of the scale, individual symptoms with
severity scores ≥7 were considered very severe. Ques-
tions evaluating emotional impact and burden of disease
were evaluated on a scale that ranged from 1 (not at all)
to 5 (a great deal). Comorbidities were based on re-
spondent answers to questions about “current medical
conditions” and were not confirmed with medical re-
cords (eg, “leukemia” could represent any leukemia sub-
type or other blood disorders that respondents correctly
or incorrectly considered to be leukemia).
Statistical methods
Study findings were analyzed using descriptive statistics.
The survey included a core set of mandatory questions
that required answers before completion. Analyses based
on optional questions excluded all respondents who did
not provide an answer. Respondent outcomes were ex-
amined by respondent-reported symptom severity quar-
tile and calculated prognostic risk scores. To identify
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trends related to the effect of MPN symptom severity on
activities of daily living and work productivity, respon-
dents were stratified by disease-related symptom severity
quartile using abbreviated (10-item) MPN-SAF total
symptom scores (MPN-SAF TSS) [4]. Previous studies of
MPN-SAF TSS quartiles in patients with MPNs found
that higher quartiles were associated with increased
measures of disease severity (eg, presence of cytopenias,
prior thrombosis, individual symptom scores) [15, 16].
On a scale of 0 (absent) to 100 (worst imaginable),
symptom severity quartiles were determined after survey
data collection in an effort to include similar numbers of
respondents in each quartile and were defined as fol-
lows: quartile 1, 0–5; quartile 2, 6–13; quartile 3, 14–26;
quartile 4, 27–78. Respondents were also stratified by
prognostic risk scores to identify trends related to the ef-
fects of risk scores on activities of daily living and work
productivity. Prognostic risk scores were calculated
based on information provided by respondents regarding
medical history events and laboratory values at any point
between diagnosis and the time of the survey and were
generated using published scoring systems for MF (Dy-
namic International Prognostic Scoring System) [12], PV
(modified from Tefferi et al.) [13], and ET (International
Prognostic Score for Essential Thrombocythemia) [14]
(Additional file 1: Table S1). Respondents who could not
recall required information for prognostic risk score cal-
culations were excluded from the related subgroup ana-
lyses. This report analyzed quartile 1 and quartile 4
symptom severity subgroups and low- and high-risk
prognostic risk score subgroups in an effort to focus on
(1) respondents with potentially underappreciated MPN
disease severity (ie, those with the lowest symptom se-
verity or low prognostic risk) and (2) respondents with
the potentially greatest disease severity (ie, those with
the highest symptom severity and/or high prognostic
risk).
Ethics, consent and permissions
The study received approval from the ICF International
internal ethics review board, which is registered with the
US Department of Health and Human Services Office of
Human Research Protections and has Federalwide As-
surance (FWA #00000845; ethics review board chair,
Janet Griffith, PhD). ICF International assisted in con-




The survey was completed by 813 respondents (MF, n =
207; PV, n = 380; ET, n = 226), representing 47 states and
the District of Columbia. Most respondents were
women; 98 % were white (Table 1). The median age was
similar between groups (MF, 66 years; PV, 64 years; ET,
62 years), and a subgroup of respondents were <50 years
of age at diagnosis (MF, 19 %; PV, 27 %; ET, 43 %).
Nearly all respondents reported being covered by some
form of health insurance, predominantly group commer-
cial insurance or Medicare. A subset of respondents re-
ported that they relied on a caregiver (either “rarely,”
“sometimes,” or “often”) because of their MPN (MF,
41 %; PV, 22 %; ET, 15 %).
Disease features
Median disease durations for respondents with MF, PV,
and ET were 4 years, 7 years, and 7 years, respectively
(Table 1). Most respondents had an intermediate or high
prognostic risk score calculated using information col-
lected during the survey and previously published scor-
ing systems described in Additional file 1: Table S1.
A subgroup of respondents had comorbidities at the
time of the survey (MF, 44 %; PV, 37 %; ET, 37 %). The
most frequently reported comorbidities for respondents
with MF were diabetes (6 %), moderate to severe kidney
disease (6 %), emphysema/chronic obstructive pulmon-
ary disease (COPD)/chronic bronchitis (5 %), and
leukemia (5 %); for respondents with PV, diabetes (7 %),
connective tissue disorders (6 %), moderate to severe
kidney disease (5 %), and emphysema/COPD/chronic
bronchitis (5 %); and for respondents with ET, moderate
to severe kidney disease (5 %), myocardial infarction
(4 %), diabetes (4 %), solid tumor (4 %), and narrowing
and hardening of the arteries to the limbs (4 %).
Symptom burden
In agreement with other reports in patients with MPNs
[4, 5, 18], the MPN Landmark survey respondent popu-
lation reported a broad symptom burden; Table 2 pre-
sents the mean scores and incidences of symptoms
included in the MPN-SAF TSS for respondents who ex-
perienced symptoms within the last 12 months. Among
respondents with MF, the mean MPN-SAF TSS was
more severe in those with higher versus lower calculated
prognostic risk scores (MPN-SAF TSS in highest vs low-
est prognostic risk category, 30.8 vs 8.1). However, this
trend was not observed among respondents with PV
(MPN-SAF TSS in highest vs lowest prognostic risk cat-
egory, 16.2 vs 16.8) or ET (13.1 vs 18.1, respectively). A
subset of respondents reported that their symptoms
were very severe (ie, severity score of ≥7 out of 10;
Additional file 1: Fig. S1). Most respondents had symp-
toms at diagnosis (MF, 78 %; PV, 88 %; ET, 81 %), with
fatigue being the most frequently reported.
Many respondents reported that ≥1 MPN-related
symptom manifested ≥1 year before diagnosis (MF, 49 %;
PV, 61 %; ET, 58 %). Notable proportions of respondents
with MF reported that fatigue (29 %) and difficulty
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Table 1 Respondent characteristics
MF (n = 207) PV (n = 380) ET (n = 226)
Median (range) age, y 66 (28–90) 64 (25–94) 62 (23–87)
Women, n (%) 112 (54) 237 (62) 163 (72)
Race,a n (%)
White 203 (98) 371 (98) 221 (98)
Black or African American 2 (1) 3 (1) 2 (1)
Asian 1 (<1) 4 (1) 2 (1)
Unknown 1 (<1) 2 (1) 1 (<1)
Median (range) disease duration since diagnosis, y 4 (0–36) 7 (0–61) 7 (0–36)
Calculated prognostic risk score, n (%)
Low 9 (4) 26 (7) 46 (20)
Intermediate-1 34 (16) 77 (20) 86 (38)
Intermediate-2 84 (41) 62 (16) NAb
High 63 (30) 101 (27) 35 (16)
Missingc 17 (8) 114 (30) 59 (26)
Primary medical insurance, n (%)
Medicare 94 (45) 157 (41) 84 (38)
Group commercial insurance 80 (39) 169 (45) 103 (46)
Individual commercial insurance 14 (7) 25 (7) 18 (8)
Medicaid or state assistance 1 (<1) 3 (1) 1 (<1)
Tricare or VA benefit 6 (3) 4 (1) 8 (4)
Medicare and group insurance through current/former employer 3 (1) 3 (1) 2 (1)
Medicare and secondary/supplemental insurance 3 (1) 2 (1) 2 (1)
Other 5 (2) 13 (3) 5 (2)
Unknown 1 (<1) 2 (1) 0
Education, n (%)
No high school 1 (<1) 0 0
Some high school 0 1 (<1) 1 (<1)
High school graduate 17 (8) 33 (9) 20 (9)
Technical postsecondary 7 (3) 11 (3) 11 (5)
Some college 48 (23) 88 (23) 63 (28)
Four-year college graduate 67 (32) 116 (31) 58 (26)
Postgraduate degree 67 (32) 131 (35) 73 (32)
Household income, n (%)
≤$15,000 6 (3) 12 (3) 9 (4)
15,001–$25,000 9 (4) 21 (6) 9 (4)
25,001–$35,000 19 (9) 22 (6) 11 (5)
35,001–$50,000 17 (8) 37 (10) 22 (10)
50,001–$75,000 34 (16) 62 (16) 35 (16)
75,001–$100,000 47 (23) 53 (14) 60 (27)
>$100,000 62 (30) 145 (38) 67 (30)
Unknown 13 (6) 28 (7) 13 (6)
ET = essential thrombocythemia; MF =myelofibrosis; NA = not applicable; PV = polycythemia vera; VA = Veterans Affairs
aRespondents were allowed to give multiple answers regarding race; this table records only the first answer given by each respondent
bRespondents with ET could receive prognostic risk scores of low, intermediate, or high; intermediate was not divided into intermediate-1 and -2
cCalculated prognostic risk score missing because of unknown lab values for risk categorization
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sleeping (15 %) manifested ≥1 year before diagnosis. Re-
spondents with PV and ET reported that the most com-
mon symptoms to manifest ≥1 year before diagnosis
were fatigue (26 % and 23 %, respectively) and headaches
(16 % and 16 %).
Quality of life, activities of daily living, and work
productivity
Many respondents reported that their MPN-related
symptoms reduced their QoL (MF, 81 %; PV, 66 %; ET,
57 %). Reduced QoL due to MPN-related symptoms was
self-reported even by respondents with low calculated
prognostic risk scores (MF, 67 %; PV, 62 %; ET, 57 %)
and those in the lowest symptom severity quartile (MF,
51 %; PV, 33 %; ET, 15 %; Fig. 1).
A notable proportion of respondents reported that
their MPN interfered with activities of daily living
(Table 3). Many respondents (≥45 %) in each group re-
ported that their activities were limited by pain/discom-
fort; some respondents (MF, 12 %; PV, 10 %; ET, 7 %)
reported that this occurred “a great deal” (Table 3).
More than 10 % of respondents in each group reported
that their MPN caused the cancelation of planned activ-
ities in ≥4 of the preceding 30 days (Table 3). Among re-
spondents with low prognostic risk scores, ≥35 %
reported canceling ≥1 day of planned activities in the
preceding 30 days because of their condition (Fig. 1).
Most respondents reported feeling anxious or worried
about their MPN (MF, 91 %; PV, 78 %; ET, 74 %) and
63 % of respondents with PV reported stress/anxiety re-
lated to managing their hematocrit at <45 %. Many
respondents reported feeling depressed (MF, 75 %; PV,
60 %; ET, 59 %) and/or angry (MF, 43 %; PV, 38 %; ET,
38 %). Some respondents had difficulty coping with
stress (MF, 50 %; PV, 46 %; ET, 43 %). Respondents also
reported altered sleeping habits (MF, 57 %; PV, 53 %; ET,
47 %). In addition, many respondents felt that their
MPN affected their family/social life (MF, 79 %; PV,
63 %; ET, 55 %), relationship with their caregiver (MF,
28 %; PV, 18 %; ET, 15 %), and sex life (MF, 63 %; PV,
49 %; ET, 42 %).
Many respondents reported that their MPN limited
productivity, including reduced work hours, calling in
sick to work, and/or terminating their job (Table 4).
Even respondents with low calculated prognostic risk
scores reported calling in sick to work at least once
in the preceding 30 days (Fig. 1). However, a consist-
ent trend with regard to productivity and calculated
prognostic risk scores was not observed across all 3
MPN subgroups. Greater proportions of respondents
with PV who had low prognostic risk scores reported
canceling planned activities and calling in sick to
work compared with those who had high prognostic
risk scores. Respondents in the high symptom severity
quartile of all 3 MPN subgroups called in sick to
work more often than respondents in the low symp-
tom severity quartile.
Treatment management and therapies
The most important treatment goal reported by re-
spondents with MF (42 %) or PV (25 %) was slowing
or delaying progression of their disease; prevention of
Table 2 MPN-SAF 10-item symptoms reported by MPN within the last 12 monthsa
MF (n = 207) PV (n = 380) ET (n = 226)
Symptom Mean Score Incidence, % Mean Score Incidence, % Mean Score Incidence, %
Fatigueb 5.1 80 4.6 73 4.3 71
Abdominal discomfort 2.3 53 1.4 35 1.3 31
Night sweatsc 2.3 51 2.0 45 1.9 38
Early satiety 2.0 37 1.1 22 1.0 21
Bone paind 2.0 40 1.2 23 1.2 27
Inactivity 1.9 31 1.5 24 1.0 19
Itching 1.8 40 2.9 55 1.4 33
Weight loss 1.6 28 0.5 12 0.5 10
Concentration problems 1.5 29 2.0 36 1.9 35
Fever 0.6 14 0.2 5 0.2 6
MPN-SAF TSS 21.2 NA 17.4 NA 14.8 NA
ET = essential thrombocythemia; MF =myelofibrosis; MPN =myeloproliferative neoplasm; MPN-SAF TSS =Myeloproliferative Neoplasm Symptom Assessment Form
10-item total symptom score; NA = not applicable; PV = polycythemia vera
aThis table summarizes only those symptoms included in the MPN-SAF 10-item instrument and is not inclusive of all symptoms that were assessed in the MPN
Landmark survey. Symptom severity score was on a scale of 0 (absent) to 10 (worst imaginable); mean scores included in this table were calculated among those
respondents who reported experiencing the symptom (ie, score ≥1) within the 12 months preceding the survey
bPresented as “fatigue” to respondents with MF and PV and as “fatigue and tiredness” to respondents with ET
cPresented as “night sweats” to respondents with MF and ET and as “day and night sweats” to respondents with PV
dDiffuse, not joint pain or arthritis
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vascular/thrombotic events was the most important
treatment goal reported by respondents with ET
(35 %) (Table 5). A subset of respondents reported
symptom relief as their most important treatment
goal (MF, 7 %; PV, 9 %; ET, 9 %). In all MPN groups,
fatigue was the most common symptom that respon-
dents reported as the one they most wanted to re-
solve (MF, 47 %; PV, 33 %; ET, 33 %).
The therapies that respondents most often reported
receiving at any time were aspirin (59 %), ruxolitinib
(48 %), and hydroxyurea (42 %) in the MF group; phle-
botomy (90 %), aspirin (83 %), and hydroxyurea (58 %)
in the PV group; and aspirin (87 %), hydroxyurea (69 %),
and anagrelide (36 %) in the ET group.
Discussion
The MPN Landmark survey is the first large survey to
evaluate the experience of patients with MPNs in a con-
temporary US population and is the first study to exten-
sively evaluate effects of MPNs on productivity and
employment. The survey findings suggest that patients
with MPNs experience a broad symptom burden and re-
ductions in QoL, functional status, activities of daily liv-
ing, and work productivity. These findings support
recent reports of symptom burden and QoL that in-
cluded non-US patient populations [4, 5, 17].
Increased recognition of the full disease burden associ-
ated with MPNs will help identify patients with unmet

























































































































Fig. 1 Impact of MPNs on QoL, work, and activities of daily living. MPN impact was stratified by calculated prognostic risk score and symptom
severity quartile in respondents with (a) MF, (b) PV, and (c) ET. ET = essential thrombocythemia; MF =myelofibrosis; MPN =myeloproliferative
neoplasm; PV = polycythemia vera; Q1 = quartile 1; Q4 = quartile 4; QoL = quality of life. *≥ 1 day in the preceding 30 days
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Table 3 MPN effect on activities of daily living
Effect on Activities, n (%) MF (n = 207) PV (n = 380) ET (n = 226)
Interfered with daily activitiesa
At allb 110 (53) 181 (48) 84 (37)
A great dealc 43 (21) 36 (10) 15 (7)
Interfered with family or social lifea
At allb 163 (79) 241 (63) 125 (55)
A great dealc 35 (17) 43 (11) 18 (8)
Activities limited by pain/discomforta
At allb 127 (61) 197 (52) 101 (45)
A great dealc 25 (12) 36 (10) 15 (7)
Days canceling planned activitiesd
1–3 44 (21) 68 (18) 41 (18)
4–6 22 (11) 26 (7) 14 (6)
7–9 2 (1) 0 3 (1)
10–12 7 (3) 9 (2) 4 (2)
13–15 3 (1) 2 (1) 1 (<1)
≥16 8 (4) 6 (2) 1 (<1)
Days spent in bed (all or most of the day)d
1–3 38 (18) 54 (14) 30 (13)
4–6 13 (6) 15 (4) 10 (4)
7–9 1 (<1) 4 (1) 5 (2)
10–12 4 (2) 2 (1) 5 (2)
13–15 4 (2) 5 (1) 1 (<1)
≥16 7 (3) 9 (2) 5 (2)
ET = essential thrombocythemia; MF =myelofibrosis; MPN =myeloproliferative neoplasm; PV = polycythemia vera
aEver
bA score >1 on a scale of 1 (not at all) to 5 (a great deal)
cA score of 5 on a scale of 1 (not at all) to 5 (a great deal)
dIn the preceding 30 days
Table 4 Effect of MPNs on work and productivity among respondents who were employed
Effect on Work/Productivity,a n/Nb (%) MF (n = 207) PV (n = 380) ET (n = 226)
Reduced work hoursc 70/119 (59) 91/246 (37) 50/169 (30)
Days sick from workd
1–3 11/52 (21) 19/127 (15) 18/88 (20)
4–6 3/52 (6) 4/127 (3) 2/88 (2)
7–9 0 0 0
≥10 1/52 (2) 1/127 (1) 0
Voluntarily terminated jobc 39/125 (31) 54/254 (21) 19/169 (11)
Involuntarily terminated jobc 6/120 (5) 11/242 (5) 7/168 (4)
Medical disabilityc 38/134 (28) 37/253 (15) 12/177 (7)
Early retirementc 38/125 (30) 54/253 (21) 24/169 (14)
ET = essential thrombocythemia; MF =myelofibrosis; MPN =myeloproliferative neoplasm; PV = polycythemia vera
aRespondents employed full- or part-time only
bN is the number of respondents who reported “yes” or “no,” excluding those who answered “not applicable.”
cEver
dIn the preceding 30 days
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and is an important step toward improving patient care.
Findings of this survey suggest that prognostic risk score
may not capture all aspects of MPN disease burden. Not-
ably, respondents with low prognostic risk scores reported
experiencing disease burdens that may be underreported
and underappreciated, highlighting an unmet need among
patients with low prognostic risk scores. Mean MPN-SAF
TSS values were actually higher (ie, more severe) in re-
spondents with PV or ET who had low prognostic risk
scores compared with those who had high risk scores.
This discordance between prognostic risk score and
MPN-SAF TSS was not observed in respondents with MF
and may be explained by the inclusion of constitutional
symptoms in the risk category calculation for MF but not
PV or ET (Additional file 1: Table S1).
Symptoms related to MPNs are informative for early
diagnosis and assessing patient clinical needs, but it is
not uncommon for patients to experience symptoms
well in advance of a formal diagnosis. Nearly one half of
respondents with MF and the majority of respondents
with PV or ET in the MPN Landmark survey reported
experiencing MPN-related symptoms ≥1 year before
diagnosis. The MPN Landmark survey also provided
new and important data regarding the negative effects of
MPNs on activities of daily living and work productivity
and indicated that respondents with the most severe
symptoms (ie, the highest symptom severity quartile)
more frequently reported negative effects on QoL, prod-
uctivity, and activities of daily living compared with the
lowest quartile. In contrast, prognostic risk score was
not consistently correlated with these measures of QoL
and functionality. Improvements in symptom recogni-
tion and treatment may help ameliorate these negative
effects.
Patient care in the MPN setting may be improved with
updated management strategies. This study highlights
the importance of using surveys or questionnaires—such
as the MPN-SAF, the Cancer Support Source™ distress
screening tool [18], or similar systematic approaches—to
accurately capture patient-reported disease burden on a
regular basis. Furthermore, participation in registries,
such as the Cancer Experience Registry [19], may help
communicate general patient symptoms and unmet
needs to the broader field. Some symptomatic patients,
including those with low prognostic risk scores, may
benefit from a change in treatment. It will be important
for physicians and researchers to optimize prognostic
tools for identifying such patients and to evaluate poten-
tial biomarkers that could be used for making a targeted
treatment change. For example, serum cytokines may be
Table 5 Most important treatment goals
Symptom Quartile Prognostic Risk
Treatment Goal,a n (%) All Respondents Q4 Q1 High Low
MF n = 207 n = 73 n = 43 n = 63 n = 9
Slow/delay progression of condition 86 (42) 27 (37) 18 (42) 28 (44) 6 (67)
Better QoL 43 (21) 26 (36) 2 (5) 16 (25) 0
Healthy blood counts 23 (11) 6 (8) 10 (23) 5 (8) 1 (11)
Symptom improvement 14 (7) 5 (7) 1 (2) 1 (2) 1 (11)
Reduction in spleen size 13 (6) 2 (3) 5 (12) 3 (5) 0
Reduce blood transfusions 12 (6) 4 (6) 2 (5) 6 (10) 0
PV n = 380 n = 98 n = 88 n = 101 n = 26
Slow/delay progression of condition 96 (25) 23 (24) 21 (24) 20 (20) 7 (27)
Prevention of vascular/thrombotic events 92 (24) 17 (17) 16 (18) 25 (25) 5 (19)
Healthy blood counts 68 (18) 10 (10) 27 (31) 22 (22) 3 (12)
Better QoL 45 (12) 19 (19) 5 (6) 11 (11) 4 (15)
Symptom improvement 33 (9) 21 (21) 1 (1) 6 (6) 2 (8)
Hematocrit levels <45 % 22 (6) 4 (4) 9 (10) 9 (9) 1 (4)
ET n = 226 n = 42 n = 71 n = 35 n = 46
Prevention of vascular/thrombotic events 78 (35) 9 (21) 28 (39) 12 (34) 15 (33)
Slow/delay progression of condition 48 (21) 8 (19) 16 (23) 5 (14) 14 (30)
Healthy blood counts 39 (17) 5 (12) 18 (25) 5 (14) 4 (9)
Better QoL 31 (14) 14 (33) 2 (3) 3 (9) 9 (20)
Symptom improvement 21 (9) 3 (7) 3 (4) 6 (17) 2 (4)
ET = essential thrombocythemia; MF =myelofibrosis; PV = polycythemia vera; QoL = quality of life
aMost important treatment goal, other than a cure, reported by ≥5 % of respondents in each MPN group
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informative biomarkers for patients with MPNs. Levels
of several serum cytokines are altered in patients with
MPNs and have been correlated with disease character-
istics, including symptoms and survival [20–22]. Further
work will be required to validate these findings and de-
termine if and how serum cytokine levels or other po-
tential biomarkers could be used in clinical practice.
Limitations of the study were primarily a result of the
descriptive design, self-reported nature of the survey,
variations in respondent demographics, and challenges
related to the relatively low prevalence of MPNs. The
study was designed to be analyzed descriptively, which
precluded statistical comparisons of the data. Because all
results were self-reported by patient respondents, in-
cluding treatments and risk factors used in the calcula-
tion of prognostic risk scores, data concerning symptom
severity, outcomes, and comorbidities were not con-
firmed with clinical measures or respondents’ treating
physicians. In addition, the sampling procedures may
have introduced self-selection biases that could have af-
fected the demographics of the respondents who partici-
pated. For example, relatively few low-risk respondents
with MF or PV completed the survey; it remains unclear
if this accurately represents the MPN population in the
United States or if more severely affected patients with
MF and PV were more motivated to participate. Respon-
dents were predominantly college educated, with a mean
annual household income > $75,000, compared with the
median US household income in 2013, which was
$52,250 [23]. In addition, although some symptom- and
QoL-related questions were adapted from the validated
MPN-SAF [5] and European Organisation for Research
and Treatment of Cancer Quality of Life Questionnaire
−Core 30 [24] instruments, the MPN Landmark survey
itself did not include use of validated QoL instruments.
As a result, the MPN Landmark survey may underrepre-
sent the symptom burden experienced by the general
MPN patient population. Because patients with MPNs
are somewhat rare, the sample needed to be recruited by
nonprobability sampling methods, which restricted the
use of probability statistics to generate sample estimates.
Notwithstanding these limitations, this was the only
feasible methodology for assessing these rare conditions
in a nationally distributed general population sample.
Conclusions
In conclusion, the MPN Landmark survey is the first
large survey of its kind. As may be expected, patient re-
spondents indicated that their most important treatment
goals were to slow/delay disease progression and to pre-
vent vascular/thrombotic events. However, the data also
suggest that the disease burden experienced by patients
with MPNs in the United States has been underreported
in the literature and negatively affects QoL, activities of
daily living, and the ability to work and be productive,
including in patients with low prognostic risk scores and
low symptom burden. MPN treatment considerations
should include reducing the symptom burden as well as
improving QoL and productivity to enhance the overall
health and lives of patients with MPNs.
Additional file
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Severe. (PDF 399 kb)
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